the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
.